Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Colorado MEDtech, CMED -- Ignore unavailable to you. Want to Upgrade?

To: WallStBum who wrote (285)	2/19/2000 2:44:00 AM
From: Paul K	Respond to of 288

(post from Yahoo speaks of CMED's DNA Diagnostic projects) Back Kicking & Screaming by: corxxx 2/14/00 9:38 am Msg: 4121 of 4130 At this juncture I would prefer to keep my mouth shut, but there is some confusion here. IMHO CMED has and will continue to be an enabler for various companies attempting to enter their respective fields with a DNA diagnostic device. Many of the companies that CMED has done work for do not have the internal expertise to do the development work necessary to bring a device through development and to the market and presumably get it through the FDA. CMED does. The disclosed client list includes, 1.) Dupont- The riboprinter, this device searches various food products in the production stage for evidence of the ecoli bacteria in the dna strand. Past discussions indicates Dupont's demand for this product continues to increase. 2.) Genprobe-Tigris, this device is one of the first blockbuster applications for DNA analysis in a commercial sense. The device which is used in blood banking applications seeks out various types of infectious (aids, hepatitis, etc) disease through analysis of the DNA strand. I believe CMED landed this through a referral from Dupont. The undisclosed formally but evidence points to list includes, 3.) Nanogen, go read popular science's august issue. This cat only got out of the bag because of its appearance on CMED's web site, which I believe has now been yanked. The extent of involvement presently is unknown. 4.) Ok hold your breath on this one, it appears that CMED was involved with early stage development of the Affymetrix product (this agains discerned from the web site.) To what extent they are still involved, if at all I have no clue. I have never heard a word mentioned or even referenced from anyone at CMED. According to Atanasoff on last CC, there are 3 or 4 more in the works or under NDA's. Secrecy is CMED's foundation and critical to its clients success, so don't expect news. My response to the comments that CMED has no proprietary leverage to these products is clear. They possess intellectual knowledge that they leverage for clients who do not possess such skills. That is what their business is and has been. CMED is an enabler of products that get to the market, perhaps its not the "pure play" that Kdd wants, but it doesn't get done without their efforts and they get paid handsomely for it (when they are on schedule which is the historical norm). I presently believe that management is working very hard on acquisitions that would be immediately accretive (big time) to net income. I'm not going to say that anything is done, but I sense some deer are in the headlights. Still way long, and getting longer CMED. See ya! --------------------------------------------------------------------------------